A 24-Week, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of 80 mg TEV-45478 Once Daily as Treatment in Adult Patients With Nonalcoholic Steatohepatitis (NASH) Who Also Have Type 2 Diabetes Mellitus

Trial Profile

A 24-Week, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of 80 mg TEV-45478 Once Daily as Treatment in Adult Patients With Nonalcoholic Steatohepatitis (NASH) Who Also Have Type 2 Diabetes Mellitus

Suspended
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs TEV 45478 (Primary)
  • Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NASH
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top